Isomorphic Labs raises $5bn for AI-driven drug discovery

A glowing molecular structure emerging from a network of crystalline AI circuits, suspended in a dark lab-like space, with faint light trails suggesting rapid formation and transformation.

Isomorphic Labs, the AI-driven drug discovery company founded by DeepMind’s Demis Hassabis, has raised $5bn in a Series C funding round—just six months after securing $2.1bn in Series B. The round, co-led by Sequoia and Greenoaks, includes participation from Andreessen Horowitz, Thrive Capital, Alphabet, GV, CapitalG, Temasek, and the Sovereign AI Fund. The investment signals deep confidence in AI’s potential to transform pharmaceutical R&D, particularly in accelerating the path from molecular insight to clinical treatment.

Breakthrough science, backed by deep pockets

Isomorphic Labs was spun out of Google DeepMind and builds on its foundational AI tools, including AlphaFold—the system that predicts protein structures and contributed to a Nobel Prize-winning breakthrough in structural biology. The company is now scaling its proprietary IsoDDE (Isomorphic Drug Design Engine), which uses advanced AI models to generate therapeutic candidates at unprecedented speed and precision. Its current research targets complex conditions such as cancer and immune disorders, areas where traditional drug discovery has faced decades of stalled progress.

The new funding will support both AI model development and clinical infrastructure. Isomorphic plans to deepen its foundational biology models, expand into new biological systems, and advance its first wave of therapeutic programs into clinical trials. According to CEO Demis Hassabis, the goal is to model biology at the molecular level and drastically shorten the drug development timeline.

UK-born, global in ambition

Though headquartered in London, Isomorphic operates with a global footprint, leveraging AI talent and pharmaceutical partnerships across the US and Europe. The UK remains a strategic base for AI research, supported by institutions like DeepMind and a growing ecosystem of AI-health startups. However, the scale of this funding—among the largest ever for a European biotech—highlights the increasing dependence on US-based venture capital to commercialise frontier science.

The involvement of Alphabet and its subsidiaries (GV and CapitalG) is notable, reflecting ongoing ties to Google’s AI infrastructure. While Isomorphic uses DeepMind-developed software, it operates independently. Still, reliance on legacy systems and proprietary AI models developed within Alphabet raises questions about long-term autonomy and data control—key concerns for founders in AI-dependent biotech.

What it means

For biotech founders and investors, this round underscores a shift: AI is no longer a supporting tool but the core engine of drug discovery. The $5bn injection allows Isomorphic to build end-to-end capabilities—from AI modelling to clinical development—without immediate pressure to monetise. This vertical integration could set a new benchmark, especially in high-cost, high-risk therapeutic areas.

However, the pace of funding raises eyebrows. Raising $7.1bn in under a year demands extraordinary validation of technical progress. While Isomorphic reports weekly scientific advancements and improved molecular profiles, independent verification of clinical readiness remains limited. Businesses relying on similar AI-biology pipelines should scrutinise not just model performance but also scalability, regulatory alignment, and IP ownership.

Founders should also consider the trade-offs of heavy VC dependence. Investors like Sequoia and Greenoaks expect outsized returns, which may push companies toward aggressive timelines or exclusive partnerships. In contrast, public or sovereign funds—like those emerging in the UAE and Kazakhstan—may offer more flexible terms, albeit with smaller cheque sizes.

Isomorphic’s success will hinge not just on AI brilliance but on translating it into safe, approved therapies. For now, the company is betting that massive capital, combined with world-class AI and drug-hunting talent, can overcome the biopharma industry’s most stubborn bottlenecks.

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *